

الحمد لله  
الرحمن الرحيم

The background of the slide is a close-up photograph of several pink roses in various stages of bloom, set against a soft-focus green background. The roses are vibrant pink with some darker, almost magenta, buds. The green leaves and stems are visible, adding to the naturalistic feel of the slide.

# **ANTIBIOTIC STEWARDSHIP PROGRAM AND INFECTION CONTROL**

**Dr.B.Naghili  
Tabriz University of Medical Sciences**





# **Tsunami of antimicrobial resistance microorganisms**

- 
- ◆ **Antimicrobial resistance results in increased Morbidity and Mortality**
  - ◆ **Cost of health care.**

- 
- ◆ Antimicrobials account for upwards of **30% of hospital pharmacy budgets** up to **50% of antimicrobial use is inappropriate**, adding considerable cost to patient care

- 
- ◆ **Given the emergence of MDRs**
  - ◆ Pathogens and **their impact on clinical** care, **appropriate use of antimicrobial agents has become a focus of patient safety** and quality assurance along with medication errors, allergy identification, and drug-drug interactions

- 
- ◆ **Infection Control and Antimicrobial Stewardship: Our only two strategies to combat antimicrobial resistance**

- 
- ◆ The **combination** of effective **antimicrobial stewardship** with a comprehensive **infection control** program has been shown to **limit the emergence and transmission of antimicrobial-resistant bacteria**

- 
- ◆ **Antimicrobial stewardship includes not only limiting inappropriate use**

# Antimicrobial Stewardship

- ◆ The optimal selection, **dose**, and **duration** of an antimicrobial that results in the **best clinical outcome** for the treatment of infection, with minimal toxicity to the patient and minimal impact on subsequent development of resistance

# Primary goal

- ◆ Optimize clinical outcomes while minimizing unintended consequences of antibiotic use toxicity
- ◆ Selection of pathogenic bacteria (eg, *C difficile*)
- ◆ Emerging resistance





## Secondary goal

- **Reduce healthcare cost without compromising quality of care**

- 
- ◆ **The ultimate goal** of antimicrobial stewardship is to improve patient care and health care outcomes.

- 
- ◆ Collaboration between the **antimicrobial stewardship team** and the **hospital infection control** and **pharmacy and therapeutics committees** or their equivalents is essential

# **Infection Control Staff and Hospital Epidemiologists**

- ◆ **The problem of spread of antimicrobial-resistant organisms within hospitals has long been a concern of infection control professionals**
- ◆ **While some resistant organisms have primarily been thought to be infection control problems and others antibiotic-use problems, an absolute distinction is artificial and both transmission and selection play important roles in the spread of antimicrobial resistance**

# **Infection Control Staff and Hospital Epidemiologists (Cont'd)**

- ◆ Infection control staff gather highly detailed data on nosocomial infections which may assist in the antimicrobial stewardship team's evaluation of the outcomes of their strategies
- ◆ Hospital epidemiologists have the expertise in surveillance and study design to lend to efforts studying the effect of antimicrobial stewardship measures

# **Infection Control Staff and Hospital Epidemiologists (Cont'd)**

- ◆ **In turn, antimicrobial stewardship programs may be able to assist in efforts to control outbreaks by focused monitoring and/or restriction of antimicrobials in the targeted units.**
- ◆ **Any antimicrobial stewardship program should either be fully integrated with or work closely with a hospital's infection control program**
- ◆ **Such collaboration has the opportunity to synergistically reduce antimicrobial resistance and improve patient outcomes**

# Antimicrobial prescribing facts: the 30% rule

- ◆ ~ 30% of all hospitalized inpatients at any given time receive antibiotics
- ◆ Over 30% of antibiotics are prescribed inappropriately in the community
- ◆ Up to 30% of all surgical prophylaxis is inappropriate
- ◆ ~ 30% of hospital pharmacy costs are due to antimicrobial use
- ◆ 10-30% of pharmacy costs can be saved by antimicrobial stewardship programs




# **Surveillance of antimicrobial use and resistance**

- ◆ **Adapt empiric treatment according to local resistance trends**
- ◆ **Demonstrate changes in practice over time.**
- ◆ **Identify wards with high antimicrobial usage or use of non-policy antimicrobials and define targeted interventions required**

# Communicate


- ◆ Communication is a key component of the success of an ASP
- ◆ . clear, simple communication should show the vision and the benefits of the program, with core clinical messages.
- ◆ The “**Start Smart** - **thenFocus**” approach in the UK is a good example of such an approach

Figure 7. Model of Antimicrobial Prescribing Pathway and Organization in Acute Hospitals in Scotland.



Adapted from Nathwani D. et al, *J. Antimicrob. Chemother.* 2006;57:1189-1196.

Figure 9. Front- and Back-end Antimicrobial Stewardship Strategy.



Adapted from Chung GW et al. *Virulence* 2013; 4:1-7.

# ANTIMICROBIAL STEWARDSHIP

**Right drug, right dose, right time, right duration...  
...every patient**

**Then  
focus**

## Start Smart

**Do not start antibiotics  
in the absence of evidence  
of bacterial infection**

- Take history of relevant allergies
- Initiate prompt effective antibiotic treatment within one hour of diagnosis (or as soon as possible) in patients with life threatening infections
- Comply with local prescribing guidance
- Document clinical indication and dose on drug chart and clinical notes
- Include review/stop date or duration
- Ensure relevant microbiological specimens taken

## Clinical review & decision\* at 48 hours

Clinical review check microbiology,  
make and document decision\*

**1. STOP**

**2. IV/oral switch**

**3. Change:** to narrow  
spectrum agent

**4. Continue  
and review  
after 4 hours**

**5. OPAT\*\***

**DOCUMENT DECISION**

\* Antimicrobial Prescribing Decision  
\*\* Outpatient Parenteral Therapy

# Shorter Is Better

- ◆ Many traditional antibiotic courses are unnecessarily long
- ◆ Durations of antibiotic therapy for most bacterial infections are based on the fact that the week has 7 days in it, resulting in traditional 7 -14 day antibiotic courses
- ◆ The modern week has 7 days in it because the Roman Emperor Constantine the Great said so in 321 CE
- ◆ Had Constantine chosen a 4-day week, providers would likely routinely prescribe 4-8 day courses of therapy

# Shorter Is Better

- ◆ Fortunately, in the last 25 years, clinical investigators have clarified necessary antibiotic durations by conducting over 40 randomized controlled trials (RCT) comparing short-course vs. traditional courses of antibiotics for a variety of bacterial infections
- ◆ Short-course therapy was just as effective as longer courses, and often with better point estimates of clinical success, fewer adverse events, and/or diminished emergence of resistance at the site of infection

# Shorter Is Better

- ◆ **Fernandez-Lazaro et al conducted an exhaustive retrospective study of 5.6 million outpatient antibiotic courses prescribed by 10,616 Family Medicine specialists in Ontario, Canada from March 2016 to February 2017.**
- ◆ **Unfortunately, the authors found that the median duration of antibiotic regimens was 7-8 days (38%), under 25% of prescriptions were shorter than 7 days, and substantially more than 30% were for longer than 8 days.**
- ◆ **Such long durations of therapy are unlikely warranted for most routine bacterial infections treated with outpatient oral antibiotics**

# Shorter Is Better

- ◆ By multivariate analysis the authors found that early career physicians (<11 years since graduation from medical school) were significantly less likely to prescribe prolonged courses than mid- or late-career physicians.
- ◆ Late-career physicians ( $\geq 25$  years since medical school) did the worst. Other factors associated with prolonged courses included practice in a rural setting, patients with more co-morbidities, and patients who cared for proportionately more children

| Diagnosis                                                          | Short (d) | Long (d)    | Result |
|--------------------------------------------------------------------|-----------|-------------|--------|
| Community Acquired Pneumonia<br>[23-31]                            | 3 or 5    | 7, 8, or 10 | Equal  |
| Hospital Acquired/Ventilator<br>Associated Pneumonia [32, 33]      | 7-8       | 14-15       | Equal  |
| Complicated Urinary Tract<br>Infections/Pyelonephritis [34-39]     | 5 or 7    | 10 or 14    | Equal  |
| Complicated/Post-Operative Intra-<br>Abdominal Infections [40, 41] | 4 or 8    | 10 or 15    | Equal  |
| Gram Negative Bacteremia [42]                                      | 7         | 14          | Equal  |
| Acute Exacerbation of Chronic                                      | $\leq 5$  | $\geq 7$    | Equal  |

|                                |                                  |                                                                                          |       |
|--------------------------------|----------------------------------|------------------------------------------------------------------------------------------|-------|
| Chronic Osteomyelitis [47]     | 42                               | 84                                                                                       | Equal |
| Empiric Neutropenic Fever [48] | afebrile<br>and stable<br>x 72 h | Afebrile and stable x 72 h<br>and with absolute neutrophil<br>count > 500 cells/ $\mu$ l | Equal |

# Shorter Is Better

- ◆ **Yahav et al. report the first RCT comparing shorter course (7 days) versus longer course (14 days) antibiotic treatment for adult patients with Gram negative bloodstream infection.**
- ◆ **The investigators enrolled 604 patients with Gram negative bloodstream infection across 3 academic centers , and randomized them to either 7 or 14 days of treatment – with all other aspects of treatment left to the discretion of the clinical team.**
- ◆ **The results indicated that 7 day treatment was non-inferior to 14 day treatment (45.8% vs 48.3%, risk difference -2.6%, 95%CI -10.5 to +5.3%)**

| Outcome                                                                        | Short Arm (7 d)<br>(n = 306)                 | Long Arm (14 d)<br>(n = 298)                  | Risk Difference<br>(95% CI) | P<br>Value       |
|--------------------------------------------------------------------------------|----------------------------------------------|-----------------------------------------------|-----------------------------|------------------|
| Primary outcome                                                                | 140 (45.8)                                   | 144 (48.3)                                    | −2.6 (−10.5 to 5.3)         | .527             |
| 90-d all-cause mortality                                                       | 36 (11.8)                                    | 32 (10.7)                                     | 1.0 (−4.0 to 6.1)           | .702             |
| Readmissions                                                                   | 119 (38.9)                                   | 127 (42.6)                                    | −3.7 (−11.5 to 4.1)         | .363             |
| Extended hospitalization beyond 14 d                                           | 15 (4.9)                                     | 19 (6.4)                                      | −1.5 (−5.1 to 2.2)          | .483             |
| Distant complications                                                          | 2 (0.7)                                      | 1 (0.3)                                       | ...                         | 1.0              |
| Relapse of bacteremia                                                          | 8 (2.6)                                      | 8 (2.7)                                       | −0.07 (−2.6 to 2.5)         | .957             |
| Suppurative complications                                                      | 16 (5.2)                                     | 10 (3.4)                                      | 1.8 (−1.4 to 5.1)           | .257             |
| 14-d mortality                                                                 | 7 (2.3)                                      | 4 (1.3)                                       | 0.95 (−1.42 to 3.44)        | .288             |
| 28-d mortality                                                                 | 15 (4.9)                                     | 13 (4.4)                                      | 0.54 (−2.98 to 4.06)        | .753             |
| New clinically or microbiologically documented infection                       | 70 (22.9)                                    | 68 (22.8)                                     | 0.06 (−6.6 to 6.8)          | .987             |
| Functional capacity: needs assistance/dependent in ADL<br>or bedridden at 30 d | 150 (51.4) (n = 292)                         | 163 (57.2) (n = 285)                          | −5.8 (−13.9 to 2.3)         | .031             |
| Resistance development                                                         | 33 (10.8)                                    | 29 (9.7)                                      | 1.0 (−3.7 to 5.9)           | .690             |
| Time to return to baseline activity, wk (90 d)                                 | 2 (0–8.3) (n = 218)                          | 3 (1–12) (n = 222)                            | ...                         | <b>.010</b>      |
| Total hospital days (90 d from randomization)—survivors                        | 3 (1–9) (n = 270 alive at day 90)            | 3.5 (1–10) (n = 266 alive at day 90)          | ...                         | .923             |
| Total hospital days (90 d from randomization)—all                              | 4 (1–10)                                     | 4 (1–12)                                      | ...                         | .603             |
| Duration of appropriate antibiotic therapy for bacteremia                      | 7 (7.0–8.0)                                  | 14.0 (14.0–14.0)                              | ...                         | <b>&lt; .001</b> |
| Total antibiotic days from culture collection to day 90<br>postrandomization   | 10.0 (9.0–18.0)<br>(n = 270 alive at day 90) | 16.0 (15.0–22.0)<br>(n = 266 alive at day 90) | ...                         | <b>&lt; .001</b> |
| Adverse events                                                                 |                                              |                                               |                             |                  |
| Acute kidney injury                                                            | 14 (4.6)                                     | 12 (4.0)                                      | 0.5 (−2.7 to 3.8)           | .842             |
| Liver function abnormalities                                                   | 16 (5.2)                                     | 20 (6.7)                                      | −1.5 (−5.3 to 2.3)          | .494             |
| Diarrhea during hospital stay                                                  | 17 (5.6)                                     | 23 (7.7)                                      | −2.2 (−6.1 to 1.8)          | .285             |
| Diarrhea until day 90 <sup>a</sup>                                             | 49 (16)                                      | 54 (18.1)                                     | −2.1 (−8.1 to 3.9)          | .491             |
| Rash                                                                           | 2 (0.7)                                      | 4 (1.4)                                       | ...                         | .445             |
| <i>Clostridium difficile</i> infection                                         | 3 (1.0)                                      | 1 (0.3)                                       | ...                         | .322             |

# Shorter Is Better

- ◆ The study suggests that 7 days of treatment may be sufficient for hospitalized non-critically ill patients with Gram negative bacteremia with signs of early response to treatment.
- ◆ Evidence-informed shortening durations of antibiotic treatment offers the best approach to a clinical cure of patients with bacteremia, while minimizing potential patient- and population-level harms of antimicrobial treatment

# **Antibiotic stewardship is the effort**

- ◆ **To measure antibiotic prescribing**
- ◆ **To improve antibiotic prescribing by clinicians and use by patients so that antibiotics are only prescribed and used when needed**
- ◆ **To minimize misdiagnoses or delayed diagnoses leading to underuse of antibiotics**
- ◆ **To ensure that the right drug, dose, and duration are selected when an antibiotic is needed**